Mavorixafor for Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
Do I need to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications. However, it does mention that participants should not have used any investigational drugs recently and should not use drugs of abuse. It's best to discuss your specific medications with the trial team.
Who Is on the Research Team?
Chief Medical Officer
Principal Investigator
X4 Pharmaceuticals, Inc.
Are You a Good Fit for This Trial?
This trial is for healthy men and women to study how mavorixafor interacts with other drugs. Participants must meet certain health criteria, but specific inclusion and exclusion details are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive mavorixafor and either carbamazepine or efavirenz to assess drug-drug interactions
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Carbamazepine
- Efavirenz
- Mavorixafor
Find a Clinic Near You
Who Is Running the Clinical Trial?
X4 Pharmaceuticals
Lead Sponsor